AARDVARK THERAPEUTICS, INC. Financing Cash Flow
AARDVARK THERAPEUTICS, INC. (AARD) reported Financing Cash Flow of $266.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- AARDVARK THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $262.00K.
- AARDVARK THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $4.00K, a 100.00% decline year-over-year.
- AARDVARK THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $274.00K.
- AARDVARK THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $171.00K, a 167.19% increase year-over-year.
- AARDVARK THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $89.25M, a 8.85% increase from fiscal 2024.
- AARDVARK THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $81.99M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $262.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $266.00K 10-Q · filed 2026-08-11 | $540.00K derived: sum of 3 quarters · filed 2026-08-11 | $711.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $4.00K 10-Q · filed 2026-05-07 | $278.00K derived: sum of 2 quarters · filed 2026-05-07 | $449.00K derived: sum of 3 quarters · filed 2026-05-07 | $378.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $274.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $445.00K derived: sum of 2 quarters · filed 2026-03-23 | $374.00K derived: sum of 3 quarters · filed 2026-08-11 | $89.25M 10-K · filed 2026-03-23 |
| 2025-09-30 | $171.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $100.00K derived: sum of 2 quarters · filed 2026-08-11 | $88.97M 10-Q · filed 2025-11-13 | $87.96M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $88.80M 10-Q · filed 2026-08-11 | $87.79M derived: sum of 3 quarters · filed 2026-08-11 | $87.85M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $88.88M 10-Q · filed 2026-05-07 | $87.86M derived: sum of 2 quarters · filed 2026-05-07 | $87.92M derived: sum of 3 quarters · filed 2026-05-07 | $170.87M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$950.00K derived: sum of 2 quarters · filed 2026-03-23 | $81.99M derived: sum of 3 quarters · filed 2026-03-23 | $81.99M 10-K · filed 2026-03-23 |
| 2024-09-30 | $64.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $83.00M derived: sum of 2 quarters · filed 2025-11-13 | $83.00M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $82.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $82.94M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |